14 New Developments in prostate cancer Promontory Therapeutics Completes Enrolment of Phase 2 Trial of PT-112 in Late-Line Patients with Metastatic CastrationResistant Prostate Cancer The target enrolment of 109 patients across clinical sites in the United States and France has been met for PT-112 according to the developers ofnPromontory Therapeutics. PT-112 is a small-molecule conjugate of pyrophosphate being studied for use in patients with late-stage metastatic castrationresistant prostate cancer (mCRPC). "This clinical trial is the largest study to date of PT-112 and will establish the optimal dose in line with the FDA's Project Optimus, as well as proof of concept in our late-line mCRPC patient population," said Promontory Therapeutics Chief Medical Ofcer Johan Baeck, MD, in the news release. PT-112 is the rst small-molecule conjugate of pyrophosphate in clinical development in oncology. PT-112 has numerous advantages — including its tolerability and inhibition of ribosomal biogenesis which leads to immunogenic cell death, through the release of damage associated molecular patterns that bind to dendritic cells and lead to downstream immune effector cell recruitment in the tumour microenvironment. The primary outcome for the study is to dene the recommended dose level and schedule for pivotal studies. Secondary outcomes include disease control rate, objective response, and duration of response. References A study evaluating the safety, pharmacokinetics, and clinical effects of intravenously administered PT-112 injection in subjects with advanced solid tumours and subsequent dose expansion cohorts. ClinicalTrials.gov. Last updated August 14, 2023. Accessed March 8, 2024. https://clinicaltrials.gov/study/NCT02266745 UROLOGY, URO-ONCOLOGY AND SEXOLOGY UPDATE
RkJQdWJsaXNoZXIy NTIyOTQ=